Tci Wealth Advisors, Inc. Editas Medicine, Inc. Transaction History

Tci Wealth Advisors, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	BUY	$9.99 - $21.35 $3,296 - $7,045	330 New	330 $4,000
Q1 2022 Apr 29, 2022	SELL	$14.08 - $27.63 $281 - $552	-20 Closed	0 $0
Q4 2021 Jan 24, 2022	SELL	$26.55 - $40.57 $4,805 - $7,343	-181 Reduced 90.05%	20 $1,000
Q3 2021 Oct 29, 2021	SELL	$39.27 - $72.94 $78 - $145	-2 Reduced 0.99%	201 $8,000
Q2 2021 Aug 02, 2021	BUY	$31.29 - $56.64 $1,689 - $3,058	54 Added 36.24%	203 $11,000
Q1 2021 Apr 29, 2021	BUY	$39.71 - $90.58 $4,884 - $11,141	123 Added 473.08%	149 $6,000
Q3 2020 Oct 20, 2020	BUY	$28.06 - $37.16 $168 - $222	6 Added 30.0%	26 $1,000
Q1 2020 Apr 14, 2020	SELL	$14.88 - $32.78 $193 - $426	-13 Reduced 39.39%	20 $0
Q4 2019 Jan 27, 2020	BUY	$19.49 - $32.63 $643 - $1,076	33 New	33 $1,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.